Mana.bio
AI-based Programmable Drug Delivery
Company Overview
Snapshot
Founded in October 2021 by Yogev Debbi and Roy Nevo, Mana.bio operates with 11–50 employees. The company has raised $24.5M across two funding rounds from five investors. In October 2023, Mana.bio secured a Seed round, with Andreessen Horowitz among the investors, to accelerate its programmable drug delivery initiatives.
Business overview
Mana.bio specializes in AI-based drug delivery solutions, with a primary focus on gene therapy. The company's core technology integrates machine learning and nanotechnology to develop advanced drug delivery systems. It has developed a platform for lipid nanoparticle development tailored for oligonucleotide therapies, including mRNA-based therapeutics, vaccines, and gene therapy, serving the broader Health Tech & Life Sciences sector.
Strategic signal
In September 2025, Mana.bio unveiled Mina, the world's first large language model-powered AI agent designed specifically for lipid nanoparticles. This launch signals a significant advancement in leveraging AI for RNA delivery, potentially accelerating the discovery and optimization of targeted therapeutic solutions and validating the company's innovative approach in the biotechnology sector.
Company Intelligence Q&A
- What is Mana.bio's primary focus?
- Mana.bio specializes in AI-based drug delivery solutions, with a particular emphasis on gene therapy, integrating machine learning and nanotechnology to develop advanced drug delivery systems.
- When was Mana.bio founded and by whom?
- Mana.bio was founded in October 2021 by co-founders Yogev Debbi and Roy Nevo.
- What was a significant product launch for Mana.bio?
- In September 2025, Mana.bio unveiled Mina, the world's first large language model-powered AI agent for lipid nanoparticles, designed to advance RNA delivery.
- What was a key funding event for Mana.bio?
- In October 2023, Mana.bio raised a Seed round, with Andreessen Horowitz and NFX Capital participating, to accelerate its programmable drug delivery initiatives.
- What recent strategic leadership addition did Mana.bio announce?
- In July 2026, Mana.bio announced the appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board, enhancing its expertise in AI-enabled lipid nanoparticle discovery.